|1.||Braeckman, Johan: 1 article (06/2014)|
|2.||Michielsen, Dirk: 1 article (06/2014)|
|3.||Rouprêt, M: 1 article (11/2011)|
|4.||Ouzaid, I: 1 article (11/2011)|
|5.||Ruiz-Hornillos, Javier: 1 article (12/2009)|
|6.||Henríquez-Santana, Aythamy: 1 article (12/2009)|
|7.||González, Inés Gonzalo: 1 article (12/2009)|
|8.||Sánchez, Sonsoles Rojo: 1 article (12/2009)|
|9.||Moreno-Fernández, Antonio: 1 article (12/2009)|
|10.||Bello, U: 1 article (04/2006)|
|1.||Prostatic Neoplasms (Prostate Cancer)
06/29/2014 - "Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study."
11/01/2011 - "Leuprolide Acetate (LA) Eligard(®)45mg was the first 6-monthly LHRH agonist (agoniste luteinizing hormone-releasing hormone [LHRHa]) treatment available for use in prostate cancer. "
04/01/2006 - "This article reviews published literature (based on a search of PubMed, EMBASE and Biosis databases to the end of 2005) and other sources of data on a new formulation of leuprorelin acetate (Eligard) for use in the treatment of hormone-dependent advanced prostate cancer. "
06/29/2014 - "The 1-, 3- and 6- month biodegradable polymer matrix depot formulations of leuprorelin acetate (Eligard(®)/Depo-Eligard(®), Astellas Pharma Inc/BV) were shown to reduce testosterone and prostate-specific antigen levels and to be well tolerated in patients with advanced prostate cancer in several clinical trials. "
|2.||Prostate-Specific Antigen (Semenogelase)
|6.||Gonadotropin-Releasing Hormone (GnRH)